Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial. J of Skin [Internet]. 2021 Nov. 5 [cited 2026 Apr. 30];5(6):s52. Available from: https://skin.dermsquared.com/skin/article/view/1403